Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers ...
Blueprint Medicines Corporation (BPMC) is a public biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core mission is to improve and extend patients’ lives by identifying and targeting the root causes of disease—especially in areas where genetic or molecular drivers can guide more precise treatment. Its work spans oncology and ...Blueprint Medicines Corporation (BPMC) is a public biopharmaceutical company headquartered in Cambridge, Massachusetts. The company’s core mission is to improve and extend patients’ lives by identifying and targeting the root causes of disease—especially in areas where genetic or molecular drivers can guide more precise treatment. Its work spans oncology and immunology/allergy or inflammation-related conditions, with an emphasis on targeted therapies that match patients to the underlying biological mechanism.
Business-wise, Blueprint is structured around discovering, developing, and advancing small-molecule and precision treatment options through clinical development and, where available, commercialization. The company’s pipeline highlights several major therapeutic areas. In mast-cell disorders and related conditions, Blueprint advances and develops KIT pathway-targeted treatments, including AYVAKIT for systemic mastocytosis (SM) and gastrointestinal stromal tumors, as well as BLU-263 (an orally administered KIT inhibitor) aimed at non-advanced SM and other mast-cell–involving indications. The company also has programs targeting cancer biology with orally potent inhibitors. For example, fisogatinib is developed for hepatocellular carcinoma, and GAVRETO is being developed for RET fusion-positive non-small cell lung cancer (NSCLC), along with other RET-altered solid tumors and medullary thyroid carcinoma.
Blueprint’s strategy also includes broader precision oncology programs tied to specific molecular alterations. The company has multiple EGFR-driven NSCLC efforts (e.g., BLU-701 and BLU-945) as well as a program specifically targeting NSCLC with EGFR exon 20 insertion mutations (BLU-451). Beyond these, the pipeline includes additional earlier- to mid-stage candidates such as BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers.
To strengthen development and expand capabilities, Blueprint has entered collaboration and licensing agreements with major industry partners, including Genentech/Roche entities, Zai Lab, and other collaborators. Such partnerships can help share clinical, regulatory, and development burdens while broadening access to expertise and geographic commercialization potential.
From a cost and financial perspective, the company’s TTM valuation and profitability indicators reflect the typical biotech profile: substantial R&D and development investment with periodic or ongoing net losses. The provided metrics show negative operating and net profit margins and negative free cash flow measures (TTM), consistent with a biotech pipeline environment where heavy expenditures precede or accompany commercialization. Liquidity ratios (e.g., current/quick ratio values in the dataset) indicate operational solvency support, but the company’s financial performance is still heavily influenced by clinical trial spend, manufacturing scale-up, regulatory progress, and milestone-driven economics.
Key leadership includes CEO Kathryn Haviland. Blueprint’s organizational and scientific focus—precision targeting of disease drivers—drives product and program selection, clinical trial design, and eventual value creation through improved response rates, better tolerability profiles, and differentiation in biomarker-defined patient populations.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$508.8M
+104.0%
+2.1%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-67.1M
+86.8%
+101.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+96.0%
+1.2%
+3.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-41.7%
+78.6%
+2.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-13.2%
+93.5%
+101.0%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-197.2M
+56.5%
-85.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-38.8%
+78.7%
-82.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
157.1%
-73.5%
-77.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.85x
-24.3%
-1.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good morning. My name is Angela and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines 1Q 2025 Earnings Release and Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer section. [Operator Instructions] Thank you. Jenna Cohen, you may begin your conference.
Jenna Cohen: Thank you, Angela. Good morning everyone and welcome to Blueprint Medicine's first quarter 2025 financial and operating results conference call. This morning, we issued a press release which outlines the topics we plan to discuss today. You can access the press release as well as the slides that we'll be reviewing today by going to the investor section of our website at www.blueprintmedicines.com. Joining me today are Kate Haviland, Chief Executive Officer; Philina Lee, Chief Commercial Officer; Becker Hewes, Chief Medical Officer; and Mike Landsittel, Chief Financial Officer. Fouad Namouni, President of Research & Development and Christy Rossi, Chief Operating Officer are also on the line and available for Q&A. Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements as outlined on Slide 3 and are subject to a number of risks and uncertainties. These may cause our actual results to differ materially including those described in our reports filed with the SEC. You're cautioned not to place any undue reliance on these forward-looking statements and Blueprint disclaims any obligation to update such statements. I'll now hand the call over to Kate.
Kate Haviland: Thank you, Jenna and good morning everyone. We at Blueprint Medicine, strive to be a standout top tier biotech company with a core focus on innovation, commercial excellence, and maintaining a durable financial profile that enables disciplined global investment across our portfolio. Following strong performance in 2024, we've continued our executionable momentum in 2025. This quarter we achieved 61% year-over-year AYVAKIT revenue growth as we continue to capture the substantial and growing multi-billion dollar commercial opportunity and systemic mastocytosis, which we expect will drive our global revenue growth well into the next decade. With every additional quarter of performance AYVAKIT progresses on the path to our goal of $2 billion in revenue by 2030. The underlying fundamental demand driven by growth and patients on therapy is the critical determinant of long-term revenue potential and we are pleased that our results in Q1 reflect continued strength in this metric as we expected. This strong fundamental growth coupled with significant favorability in our free versus paid good mix is leading us to raise our revenue guidance for the year. Philina will go into this more specifically in a moment. We also advanced our industry-leading pipeline of mass cell-directed investigational …
